It's Common. It's Potentially Serious. It's Preventable.What You Should Know About Invasive Pneumococcal Disease

Tuesday, March 1, 2011

LA)BANFaiIt 7 Coneren’'s It’s Common. It’s Potentiall Serious.It’s Preventable. What You Should Know AboutInvasive Pneumococcal Disease (NAPSA)—Did ou know that children in the U.S. ounger than 5 ears of age are at increased risk of contracting a serious condition known as invasive pneumococcal disease (IPD)?! IPD is a group of illnesses that can be life-threatening. The group includes some tpes of meningitis and bacteremia, and it’s caused b a bacterium called pneumococcus.? Armed with the facts, parents can help protect their children against IPD. Common questions parents can ask their child’s doctor include: Is m child at risk? Children ounger than 5 are at increased risk for IPD.' Invasive pneumococcal disease is often spread through sneezing, coughing, and even breathing. Children can pass it on to each other in an setting where there is close contact, such as da care.” Is vaccination an option? Vaccination can help prevent IPD in infants and oungchildren. The Centers for Disease Control and Prevention (CDC) and the American Academof Pediatrics (AAP) recommendroutine vaccination with a pneumococcal 13valent conjugate vaccine for the prevention of IPD in infants and toddlers.** In addition, the CDC and AAP recommend that children 15 months to 5 ears of age receive a single dose of a pneumococcal 13valent conjugate vaccine even if the were previousl vaccinated with four doses of Prevnar (Pneumococcal 7-valent Conjugate Vaccine [Diphtheria CRM: Protein]).24 The immune response from this schedule might be lower for the 6 additional strains (tpes Doctors sa children should be vaccinated against the several strains of a serious respirator condition. 1, 3, 5, 6A, 7F, and 19A) than if our child had received the full 4 doses of Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRMProtein]). It’s not known how medicall important this differenceis. What is different about Prevnar 13? Prevnar 13 can help protect against 6 additional strains of pneumococcus that cause IPD. Oneof the additional strains, 19A, causes nearl half the IPD in children ounger than5 in the U.S. Can antibiotics treat IPD? Antibiotics can be used to treat IPD infections. Unfortunatel, using antibiotics for the wrong reason or too often has caused them to not work at times. This is important for patients with IPD, because some strains of pneumococcus have been difficult to treat with commonantibiotics. Strain 19A, the most common strain affecting children in the U.S. toda, is frequentl antibiotic resistant. INDICATION FOR PREVNAR 13 Prevnar 13 is a vaccine approved for use in children 6 weeks through 5 ears of age (prior to the 6th birthda) Prevnar 18 is indicated for active immunization for the prevention of invasive disease caused b 13 strains of Streptococcus pneumoniae(1, 3, 4, 5, 6A, 6B, TF, 9V, 14, 18C, 19A, 19F, and 23F) IMPORTANT SAFETY INFORMATION FOR PREVNAR13 Prevnar 13 should not be given to anone with a severe allergic reaction to an component of Prevnar 13, Prevnar (Pneumococcal 7-valent Conjugate Vaccine [Diphtheria CRM: Protein]), or an diphtheria toxoid—containing vaccine Prevnar 13 ma not protect all individuals receiving the vaccine. eChildren with weakened immune sstems ma have a reduced immune response to Prevnar 13 eA temporar pause of breathing following vaccination has been observed in some infants born prematurel eThe most commonl reported serious adverse events include bronchiolitis (an infection of the lungs) (0.9%, 1.1%), gastroenteritis (inflammation of the stomach and small intestine) (0.9%, 0.9%), and pneumonia (0.9%, 0.5%) for Prevnar 13 and Prevnar (Pneumococcal 7-valent Conjugate Vaccine [Diphtheria CRM. Protein]), respectivel eThe most common side effects are redness, swelling and tenderness at the injection site, fever, decreased appetite, irritabilit, increased sleep, and decreased sleep. An side effects associated with the vaccination should be reported to our child’s health care provider Ask our child’s health care provider about the risks and benefits of Prevnar 13. Onl a health care provider can decide if Prevnar 13 is right for our child To learn more about IPD or see the Full Prescribing Information for Prevnar 13, visit www.Prevnar13.com. References 1. Centers for Disease Control and Prevention. Invasive pneumococcal disease in oung children before licensure of 13-valent pneumococcal conjugate vaccine—United States, 2007. MMWR. 2010;59(9):253-257. http://www.cde.gov/ mmwr/pdf/wk/mm5909. pdf. 2. Centers for Disease Control and Prevention. Pneumococcal disease. In: Atkinson W, Wolfe S, Hamborsk J, et al, eds. Epidemiolog and Prevention of Vaccine-Preventable Diseases. 11th ed. Washington, DC: Public Health Foundation; 2009:217-230. http://www.cde.gov/vaccines/pubs/pinkbook/ pink-chapters.htm. 3. Centers for Disease Control and Prevention. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children—Advisor Committee on Immunization Practices (ACIP), 2010. MMWR. 2010;59(9):258-261. http://www.cde.gov/mmwr/pdf/wk/mm5909. pdf. 4. American Academof Pediatrics, Committee on Infectious Diseases. Polic statement—recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polsaccharide vaccine (PPSV23). Pediatrics. 2010;126(1):186-190. 5. Pilishvili T, Lexau C, Farle MM, et al; for the Active Bacterial Core Surveillance/Emerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201:32-41. 6. Moore MR, Gertz RE Jr, Woodbur RL, et al. Population snapshot of emergent Streptococcus pneumoniae serotpe 19A in the United States, 2005. J Infect Dis. 2008;197:1016-1027. 271826-01

--- PHOTOS ---

File: 20190731-221123-20190731-221119-80434.pdf.jpg

--- FILES ---

File: 20190731-221119-80434.pdf